Home Drug IndexClinical Monograph

Salbutamol Uses, Dosage, Side Effects & Warnings | DrugsAtlas

Authoritative Clinical Reference

Therapeutic Class

Bronchodilator

Subclass

Short-acting β2-adrenergic receptor agonist (SABA)

Speciality

Pulmonology

Schedule (India)

Schedule H

Routes

Oral, Inhalation (MDI, DPI, Nebuliser), Parenteral (IV, SC)

Formulations

Inhaler (MDI): 100 mcg/actuation
Dry Powder Inhaler (DPI): 200 mcg/dose (Rotacaps, Accuhaler)
Nebuliser solution: 5 mg/mL respules; 2.5 mg/2.5 mL unit dose vials
Tablets: 2 mg, 4 mg
Oral syrup: 2 mg/5 mL
Injection (IV/SC): 500 mcg/mL (as sulphate)

Adult indications

INDICATIONS + DOSING — FOR CLINICIAN USE ONLY

Primary Indications (Approved / Standard in India)

1. Acute Bronchospasm (Asthma Exacerbation, COPD Exacerbation)

Inhalation is the preferred route for rapid bronchodilation with fewer systemic effects.

Route	Starting Dose	Titration	Usual Maintenance Dose	Maximum Dose	Clinical Notes
MDI (100 mcg/puff)	2 puffs (200 mcg)	May repeat every 20 min × 3 doses in acute attack	1–2 puffs every 4–6 hours PRN	8–12 puffs/day	Use spacer device for optimal lung deposition
Nebulised	2.5 mg in 3 mL NS	May repeat every 20 min × 3 doses in acute setting	2.5–5 mg every 4–6 hours	40 mg/day (divided doses)	Continuous nebulisation in severe cases under monitoring
SC Injection	250 mcg	May repeat after 4 hours	250–500 mcg every 4–6 hours	500 mcg every 4 hours	Reserve for situations where inhalation not feasible
IV Infusion	5 mcg/min	Increase by 1–2 mcg/min every 15–30 min	3–20 mcg/min	20 mcg/min	ICU setting only; continuous cardiac monitoring mandatory

2. Chronic Asthma — Reliever Therapy

Starting dose: 1–2 puffs (100–200 mcg) MDI/DPI as needed
Titration: Not applicable (PRN use)
Usual maintenance dose: 1–2 puffs up to four times daily when required
Maximum dose: Should not exceed 8 puffs/day regularly; frequent use indicates need for controller therapy escalation

Clinical Note: Use alongside inhaled corticosteroids (ICS) as per GINA/Indian Asthma Guidelines. Sole reliance on SABA without ICS is associated with increased mortality risk.

3. Exercise-Induced Bronchospasm (EIB) — Prophylaxis

Starting dose: 200 mcg (2 puffs MDI) 10–15 minutes before exercise
Titration: Not applicable
Usual maintenance dose: 200 mcg pre-exercise
Maximum dose: 200 mcg per occasion; if frequent EIB, consider adding LABA or optimising ICS

4. Hyperkalaemia (Adjunctive — Temporary Intracellular Potassium Shift)

ICU/Emergency setting only

Starting dose: 10 mg nebulised over 10–15 minutes
Titration: May repeat 10 mg dose if K+ remains elevated
Usual maintenance dose: 10–20 mg nebulised
Maximum dose: 20 mg single dose

Clinical Note: Always combine with insulin-dextrose therapy. Effect is temporary (shifts K+ intracellularly). Monitor serum potassium and ECG continuously. Expect K+ reduction of 0.5–1 mEq/L within 30 minutes.

Secondary Indications — Adults (Off-label)

Tocolysis in Preterm Labour

Parameter	Details
Indication	Acute tocolysis for preterm labour (24–34 weeks gestation)
Route	IV infusion
Starting dose	10 mcg/min
Titration	Increase by 5 mcg/min every 10 minutes based on uterine response
Usual range	10–45 mcg/min
Maximum dose	80 mcg/min
Duration	Up to 48 hours to allow corticosteroid effect for fetal lung maturity
Label status	OFF-LABEL
Specialist only	Yes — Obstetrics specialist supervision mandatory
Evidence basis	AIIMS Obstetrics protocols; Indian specialist practice. Nifedipine or atosiban preferred as first-line in current practice due to better safety profile

Caution: Contraindicated in maternal cardiac disease, preeclampsia, eclampsia, significant antepartum haemorrhage. Monitor maternal HR, BP, fluid balance, serum glucose, and potassium. Risk of pulmonary oedema with IV use.

Paediatric indications

PAEDIATRIC DOSING (Specialist Only)

Primary Indications (Approved / Standard in India)

1. Acute Asthma / Acute Bronchospasm

Age Group	MDI with Spacer	Nebulised	Oral (Syrup/Tablet)
<2 years	Not routinely preferred; if used: 1 puff (100 mcg) with spacer + mask, may repeat every 20 min × 3 in acute setting	0.15 mg/kg/dose (min 1.25 mg, max 2.5 mg) every 4–6 hours	Not routinely recommended
2–5 years	1 puff (100 mcg) up to every 4 hours; in acute attack: 2–4 puffs every 20 min × 3	2.5 mg every 4–6 hours	Syrup: 1–2 mg (0.1–0.15 mg/kg) TID
6–11 years	1–2 puffs every 4–6 hours PRN; in acute: 4–6 puffs every 20 min × 3	2.5–5 mg every 4–6 hours	Tablet: 2 mg TID
≥12 years	Adult dosing applies	2.5–5 mg every 4–6 hours	Tablet: 2–4 mg TID

Dosing structure:

Starting dose: As per age table above
Titration: In acute exacerbation, may give every 20 minutes for up to 3 doses, then every 1–4 hours as needed
Usual maintenance dose: PRN use only; 1–2 puffs every 4–6 hours
Maximum dose: Nebulised — 10 mg/dose in severe acute asthma under monitoring; Oral — 24 mg/day

Clinical Note: MDI with spacer (and face mask in children <4 years) is as effective as nebulisation and preferred in non-severe exacerbations. Ensure proper technique training.

2. Exercise-Induced Bronchospasm Prophylaxis (Age ≥6 years)

Starting dose: 100–200 mcg MDI 15 minutes before exercise
Titration: Not applicable
Usual maintenance dose: 200 mcg pre-exercise
Maximum dose: 200 mcg per occasion

Secondary Indications — Paediatrics (Off-label)

Hyperkalaemia in Paediatric ICU

Parameter	Details
Indication	Acute hyperkalaemia — adjunctive treatment
Route	Nebulised
Dose	2.5 mg (<25 kg) to 5 mg (≥25 kg) nebulised
Frequency	May repeat once after 30 minutes
Label status	OFF-LABEL
Specialist only	Yes — PICU setting only
Evidence basis	Extrapolated from adult data; used in AIIMS PICU protocols

Monitoring: Continuous ECG, serum potassium every 1–2 hours. Always use with insulin-dextrose.

Viral-Induced Wheeze / Bronchiolitis (Age <2 years)

Parameter	Details
Indication	Acute viral wheeze in infants
Route	Nebulised or MDI with spacer
Dose	2.5 mg nebulised or 2 puffs MDI as therapeutic trial
Duration	Single trial; continue only if objective improvement observed
Label status	OFF-LABEL — Routine use not recommended in bronchiolitis (IAP guidelines)
Specialist only	Yes
Evidence basis	Variable response; IAP guidelines note limited evidence of benefit in RSV bronchiolitis

Age Restriction Statement:
Not recommended in children below 2 years of age except under specialist supervision due to limited efficacy data and increased risk of paradoxical bronchospasm. Inhaled route strongly preferred over oral in all age groups.

Safety Monitoring in Children:

Heart rate (tachycardia common)
Serum potassium if high-dose or prolonged nebulisation
Tremor, irritability
Oxygen saturation response

Renal Adjustments

No dose adjustment required in renal impairment.

eGFR (mL/min/1.73m²)	Adjustment
>60	No adjustment
30–60	No adjustment
15–30	No adjustment; monitor for hypokalaemia
<15 or dialysis	No adjustment; use with caution; monitor potassium

Note: Salbutamol is not significantly renally excreted. However, patients with severe CKD may be more susceptible to hypokalaemia and cardiovascular effects. Use lowest effective dose.

Hepatic adjustment

Contraindications

Known hypersensitivity to salbutamol or any excipient in formulation
Uncontrolled severe cardiac arrhythmias (tachyarrhythmias)
Hypertrophic obstructive cardiomyopathy
Concurrent use with non-selective beta-blockers (e.g., propranolol, carvedilol) — antagonises bronchodilator effect
Tocolysis-specific: Maternal cardiac disease, eclampsia, severe preeclampsia, intrauterine infection, intrauterine fetal death, antepartum haemorrhage requiring immediate delivery

Cautions

Cardiovascular disease (ischaemic heart disease, heart failure, arrhythmias) — increased risk of tachycardia, palpitations
Hypertension — may cause transient BP elevation
Diabetes mellitus — may elevate blood glucose; monitor in diabetic patients on high-dose or IV therapy
Hyperthyroidism — may exacerbate cardiovascular effects
Seizure disorders — potential CNS stimulation at high doses
Hypokalaemia or concurrent use of potassium-lowering drugs
Phaeochromocytoma (theoretical concern)
Paradoxical bronchospasm — discontinue immediately if worsening wheeze after inhalation
Frequent SABA use (>2 days/week) — indicates poor asthma control; reassess controller therapy

Pregnancy

Parameter	Details
Overall safety	Considered relatively safe; one of the most commonly used bronchodilators in pregnant women with asthma
Risk category	US legacy Category C (crosses placenta; no controlled human studies showing teratogenicity)
Indian practice	First-line reliever for asthma in pregnancy per IAP/FOGSI guidelines
When to use	Inhaled route for asthma management — benefit clearly outweighs theoretical risk
Preferred alternatives	None required for inhaled use; salbutamol is standard of care
Monitoring	Maternal: heart rate, blood pressure. Fetal: heart rate monitoring if high-dose or IV use
Tocolysis caution	IV use associated with maternal tachycardia, hypotension, pulmonary oedema, hypokalaemia. Nifedipine preferred as first-line tocolytic in current Indian practice

Key Point: Uncontrolled asthma poses greater risk

Lactation

Parameter	Recommendation
Compatibility	Compatible with breastfeeding
Drug levels in milk	Low; clinically insignificant amounts excreted
Preferred alternatives	None needed; salbutamol is standard for breastfeeding mothers with asthma
Infant monitoring	Observe for irritability, feeding difficulties, or tremor if high maternal doses used

Elderly

Parameter	Recommendation
Starting dose	Lower end of adult dosing range (100 mcg MDI; 2.5 mg nebulised)
Titration	Slower; assess cardiovascular tolerance before dose increase
Specific risks	Tachycardia, palpitations, arrhythmias (especially in underlying IHD or AF); hypokalaemia; tremor more pronounced
Additional caution	Use lowest effective dose; monitor potassium if on diuretics; avoid oral formulations if possible

Major drug interactions

Drug	Interaction	Recommendation
Non-selective beta-blockers (propranolol, carvedilol, nadolol)	Antagonise bronchodilatory effect; may precipitate severe bronchospasm	AVOID combination. Use cardioselective beta-blockers (bisoprolol, metoprolol) with caution if essential
MAO inhibitors	Potentiation of cardiovascular effects; risk of hypertensive crisis	Avoid salbutamol within 14 days of MAO inhibitor use
Tricyclic antidepressants	Enhanced cardiovascular effects; risk of arrhythmias	Use with caution; monitor heart rate and blood pressure
Digoxin	Hypokalaemia induced by salbutamol may increase digoxin toxicity	Monitor serum potassium and digoxin levels

Moderate drug interactions

Drug	Interaction	Recommendation
Loop diuretics (furosemide)	Additive hypokalaemia	Monitor serum potassium; correct deficits
Thiazide diuretics	Additive hypokalaemia	Monitor serum potassium
Systemic corticosteroids	Additive hypokalaemia, especially with high doses	Monitor potassium in prolonged use
Theophylline/Aminophylline	Additive tachycardia, tremor, CNS stimulation	Use together with monitoring; dose adjustment rarely needed
Antidiabetic agents (insulin, sulphonylureas)	Salbutamol may cause hyperglycaemia, reducing efficacy	Monitor blood glucose; may need temporary dose adjustment
Xanthine derivatives	Additive cardiac stimulation	Monitor for tachyarrhythmias

Common Adverse effects

Fine tremor (especially hands)
Palpitations
Tachycardia
Headache
Muscle cramps
Nervousness/restlessness
Throat irritation and dry mouth (inhaled forms)
Transient hypokalaemia

Serious Adverse effects

Adverse Effect	Clinical Notes
Paradoxical bronchospasm	Discontinue immediately; switch to alternative bronchodilator
Severe hypokalaemia	Risk of cardiac arrhythmias; especially with high-dose nebulisation or IV use
Cardiac arrhythmias	Including atrial fibrillation, ventricular ectopics; monitor ECG in high-risk patients
QTc prolongation	Rare; risk increased with hypokalaemia or concurrent QT-prolonging drugs
Lactic acidosis	Very rare; reported with high-dose IV infusions
Pulmonary oedema	Associated with IV tocolytic use; avoid in cardiac disease
Myocardial ischaemia	Risk in patients with underlying coronary artery disease

Monitoring requirements

Phase	Parameters
Baseline	Heart rate, blood pressure, serum potassium (if high-dose or IV anticipated), blood glucose (diabetics)
During acute management	Oxygen saturation, respiratory rate, peak expiratory flow rate, heart rate, ECG (if IV used)
High-dose/IV use	Continuous cardiac monitoring, serum potassium every 4–6 hours, blood glucose
Long-term use	Frequency of SABA use (>2 days/week indicates poor control); inhaler technique assessment; asthma control parameters

Brands in India

Brand Name	Manufacturer	Notes
Asthalin	Cipla	MDI, Rotacaps, Nebuliser solution, Tablets, Syrup
Ventorlin	GlaxoSmithKline	MDI, Rotacaps, Respules
Salbair	Lupin	MDI, Nebuliser solution
Salbetol	FDC Ltd	Tablets, Syrup
Salbutamol (Generic)	Various	Available across formulations

FDC Products:

Duolin (Salbutamol + Ipratropium) — Cipla
Combimist (Salbutamol + Ipratropium) — Lupin
Levolin (Levosalbutamol) — Cipla (R-isomer variant)

Price range (INR)

Formulation	Approximate Price
MDI 100 mcg (200 doses)	₹50–₹100
DPI Rotacaps (30 caps)	₹30–₹70
Nebuliser Respules (2.5 mg/2.5 mL) per unit	₹3–₹6
Nebuliser Solution 15 mL (5 mg/mL)	₹25–₹40
Tablets (strip of 10)	₹5–₹15
Syrup 60 mL	₹15–₹35
Injection ampoule	₹10–₹30

Regulatory Note: Listed under NLEM 2022; prices regulated by NPPA for scheduled formulations. Available under government supply programmes.

Clinical pearls

Inhaled route always preferred: Oral and parenteral routes have higher systemic side effects with no added bronchodilator efficacy. Reserve oral forms for patients who cannot use inhalers despite training.
Spacer is essential: Always use spacer device with MDI for optimal drug delivery to lower airways, especially in children and elderly. Without spacer, >80% of drug deposits in oropharynx.
SABA overuse signals poor control: If patient uses reliever >2 times/week (excluding pre-exercise use), reassess ICS adherence, inhaler technique, and consider stepping up controller therapy.
Hyperkalaemia use is adjunctive only: Nebulised salbutamol provides temporary intracellular potassium shift (onset 15–30 min, duration 2–4 hours). Always use with insulin-glucose and arrange definitive therapy.
Cardiac caution: In patients with IHD or arrhythmias, use lowest effective dose. Consider ipratropium as alternative or add-on to reduce salbutamol requirement.
Combination with ipratropium: In acute severe asthma or COPD exacerbation, adding ipratropium to salbutamol provides additive bronchodilation and is recommended in emergency protocols.

Version

RxIndia v1.0 — 04 May 2025

Reference

CDSCO Drug Database and Product Inserts
Indian Pharmacopoeia 2022
National List of Essential Medicines (NLEM) 2022
National Asthma Control Programme (India)
AIIMS Treatment Guidelines (Emergency Medicine, Paediatrics)
API Textbook of Medicine (11th Edition)
IAP Asthma Guidelines
Goodman & Gilman's The Pharmacological Basis of Therapeutics
AIIMS Obstetrics Protocols (for tocolysis reference)
PGI Chandigarh PICU Protocols

⚖️

Clinical Responsibility

This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.

Content Feedback

Is this information helpful?

Help us improve our clinical database for the medical community.

RxIndia

Loading clinical data...